Eurocom Healthcare Communications appointed to work on Parkinson's Disease drug

Share Article

Eurocom Healthcare Communications has been appointed by Britannia Pharmaceuticals Ltd as the global branding agency for the Parkinson's Disease drug, APO-go.

Tony Chant, MD Eurocom Healthcare Communications

Tony Chant, MD of Eurocom Healthcare Communications

We are delighted to have the opportunity to make such a significant difference to the quality of life for Parkinson’s patients and their carers.

Healthcare communications agency Eurocom was recently appointed as the global branding agency for Britannia Pharmaceuticals' Parkinson's Disease drug, APO-go.

Commenting on the appointment, Tony Chant, Managing Director at Eurocom said, ‘We have excellent experience in the area of Parkinson’s Disease. We are delighted to be working in this field, and to have the opportunity to make such a significant difference to the quality of life for Parkinson’s patients and their carers.’

Robert Wood, Marketing Director for International Markets at Britannia Pharmaceuticals said, ‘We are delighted to be working with Eurocom Healthcare Communications and look forward to raising awareness of the benefits that APO-go can bring to people with Parkinson’s around the world. This is an exciting time for APO-go, with the launch of a pivotal efficacy study and the development of many patient focused initiatives.'

London based Eurocom Healthcare Communications is a medical communications agency offering healthcare marketing and creative communications to the worldwide consumer healthcare, medical and pharmaceutical industry.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joanna Gee
Visit website